LLY

1,107.1

+0.49%↑

JNJ

240.14

+2.2%↑

ABBV

234.01

-0.14%↓

UNH

402.54

-0.87%↓

MRK

119.77

+1.35%↑

LLY

1,107.1

+0.49%↑

JNJ

240.14

+2.2%↑

ABBV

234.01

-0.14%↓

UNH

402.54

-0.87%↓

MRK

119.77

+1.35%↑

LLY

1,107.1

+0.49%↑

JNJ

240.14

+2.2%↑

ABBV

234.01

-0.14%↓

UNH

402.54

-0.87%↓

MRK

119.77

+1.35%↑

LLY

1,107.1

+0.49%↑

JNJ

240.14

+2.2%↑

ABBV

234.01

-0.14%↓

UNH

402.54

-0.87%↓

MRK

119.77

+1.35%↑

LLY

1,107.1

+0.49%↑

JNJ

240.14

+2.2%↑

ABBV

234.01

-0.14%↓

UNH

402.54

-0.87%↓

MRK

119.77

+1.35%↑

Search

Glaukos Corp

Ouvert

SecteurSoins de santé

137.65 3.85

Résumé

Variation du prix de l'action

24h

Actuel

Min

131.81

Max

138.82

Chiffres clés

By Trading Economics

Revenu

114M

-20M

Ventes

7.5M

151M

BPA

-0.18

Marge bénéficiaire

-13.139

Employés

1,094

EBITDA

124M

-5.3M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+17.59% upside

Dividendes

By Acuity

Prochains Résultats

29 juil. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

719M

7.9B

Ouverture précédente

133.8

Clôture précédente

137.65

Sentiment de l'Actualité

By Acuity

50%

50%

143 / 342 Classement par Healthcare

Glaukos Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

À Propos Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat